These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8221671

  • 1. Sequence-specific interaction of a conformational domain of p53 with DNA.
    Srinivasan R, Roth JA, Maxwell SA.
    Cancer Res; 1993 Nov 15; 53(22):5361-4. PubMed ID: 8221671
    [Abstract] [Full Text] [Related]

  • 2. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
    Srinivasan R, Maxwell SA.
    Oncogene; 1996 Jan 04; 12(1):193-200. PubMed ID: 8552392
    [Abstract] [Full Text] [Related]

  • 3. Binding of cellular proteins to a conformational domain of tumor suppressor protein p53.
    Maxwell SA, Roth JA.
    Oncogene; 1993 Dec 04; 8(12):3421-6. PubMed ID: 8247546
    [Abstract] [Full Text] [Related]

  • 4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z.
    J Mol Biol; 2009 Jan 09; 385(1):249-65. PubMed ID: 18996393
    [Abstract] [Full Text] [Related]

  • 5. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.
    Stürzbecher HW, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR.
    Oncogene; 1992 Aug 09; 7(8):1513-23. PubMed ID: 1321401
    [Abstract] [Full Text] [Related]

  • 6. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism.
    Hainaut P, Rolley N, Davies M, Milner J.
    Oncogene; 1995 Jan 05; 10(1):27-32. PubMed ID: 7824276
    [Abstract] [Full Text] [Related]

  • 7. p53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells.
    Schmieg FI, Simmons DT.
    Oncogene; 1993 Aug 05; 8(8):2043-50. PubMed ID: 8393158
    [Abstract] [Full Text] [Related]

  • 8. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
    Niewolik D, Vojtesek B, Kovarik J.
    Oncogene; 1995 Mar 02; 10(5):881-90. PubMed ID: 7898929
    [Abstract] [Full Text] [Related]

  • 9. Complex of simian virus large T antigen and p53 can bind DNA specifically.
    Long SB, Ho HY, Chen CL, Lai MD.
    Anticancer Res; 1995 Mar 02; 15(4):1375-80. PubMed ID: 7654024
    [Abstract] [Full Text] [Related]

  • 10. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K, Li B, Bartel P, Fields S.
    Oncogene; 1993 Jun 02; 8(6):1693-6. PubMed ID: 8502489
    [Abstract] [Full Text] [Related]

  • 11. p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein.
    Martin DW, Subler MA, Muñoz RM, Brown DR, Deb SP, Deb S.
    Biochem Biophys Res Commun; 1993 Aug 31; 195(1):428-34. PubMed ID: 8395834
    [Abstract] [Full Text] [Related]

  • 12. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF, Paulsen D, Deppert W.
    Oncogene; 1996 May 02; 12(9):1941-52. PubMed ID: 8649855
    [Abstract] [Full Text] [Related]

  • 13. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R, Elkind NB, Ronen D, Rotter V.
    Oncogene; 1995 Mar 16; 10(6):1167-74. PubMed ID: 7535417
    [Abstract] [Full Text] [Related]

  • 14. Specific DNA binding by different classes of human p53 mutants.
    Rolley N, Butcher S, Milner J.
    Oncogene; 1995 Aug 17; 11(4):763-70. PubMed ID: 7651740
    [Abstract] [Full Text] [Related]

  • 15. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
    Hainaut P, Milner J.
    Cancer Res; 1993 Oct 01; 53(19):4469-73. PubMed ID: 8402615
    [Abstract] [Full Text] [Related]

  • 16. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M.
    Anticancer Res; 2001 Oct 01; 21(4A):2671-5. PubMed ID: 11724337
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. p53 DNA binding can be modulated by factors that alter the conformational equilibrium.
    McLure KG, Lee PW.
    EMBO J; 1999 Feb 01; 18(3):763-70. PubMed ID: 9927436
    [Abstract] [Full Text] [Related]

  • 20. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S, Trautwein C, Niehof M, Manns M.
    Hepatology; 1997 Apr 01; 25(4):867-73. PubMed ID: 9096590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.